Xeris Biopharma raised its 2030 revenue outlook to over $1 billion after third-quarter total revenue grew 44%. Sales of Recorlev, its hypercortisolism drug, rose 93% year on year on record referrals and new patient starts following a January sales force expansion. Management now expects Recorlev to reach $1 billion in annual net revenue three to four years sooner than previously projected. Updated ADA and EASD guidelines recommending screening for hypercortisolism in hard-to-control diabetes are widening the market. Gvoke revenue took a $4 million one-time Medicaid adjustment. A new patent extends KEVEYIS protection to 2043. Full-year R&D guidance fell to a $15 million increase over 2025, while SG&A guidance rose to a $60 million increase. The Phase III Cornerstone study for XP-8121 is on track to start by year-end, with a launch targeted for 2030.

Xeris CEO sees Recorlev nearing $1B in annual sales 3 to 4 years earlier than expected - XERS Stock On Track To Hit Over 7-year Highs. Published: Nov 05 2026, 08:10 PM IST * FB * TW * Linkdin * Whatsapp * GNFollow Us Xeris raised its FY 2026 revenue forecast to $395 million to $405 million, from $385 million to $390 million. * The firm posted a 44% surge in Q3 revenue to $107.2 million, beating analysts' estimates of $101.7 million, according to Fiscal.ai. * Q3 Recorlev sales surged 93% to $71.5 million. * Xeris sees $1 billion in total revenue in 2030, compared to an earlier forecast of about $750 million. Shares of Xeris Biopharma (XERS) surged more than 16% in premarket trading on Thursday, marking its best day in over a year, after CEO John Shannon said its lead drug to treat Cushing's Syndrome could generate $1 billion in annual sales three to four years earlier than expected. If the levels hold after the opening bell, XERS shares would climb to levels last seen in September 2019. Xeris expects over $1B revenue by 2030. Xeris posted a 44% surge in third-quarter (Q3) revenue to $107.2 million, beating analysts' estimates of $101.7 million, according to Fiscal.ai. Growth was driven by increasing demand for Recorlev, whose sales rose 93% to $71.5 million. Shannon said the Q3 results put the company "on a new growth curve," and put it on a path to achieve more than $1 billion in total revenue in 2030. It had earlier guided FY2030 revenue to about $750 million. "We now see Recorlev on a path to nearly $1 billion in annual net revenue three to four years sooner than previously expected," Shannon added. While Recorlev saw a sharp spike, sales were slightly offset by a 14% decline in sales of its severe low-blood-sugar treatment, Gvoke. The company attributed the fall to a one-time accounting adjustment. Net income rose to $11.3 million, or $0.06 per diluted share, beating consensus estimates of a $0.01 per-share loss. Xeris raises FY2026 revenue outlook. Xeris also raised its full-year 2026 revenue forecast to $395 million to $405 million, from $385 million to $390 million. The company held $131.1 million in cash and cash equivalents as of Sept. 30, up from $111 million at the end of 2025. Xeris is currently developing XP-8121, a once-weekly injection for hypothyroidism. The company expects to begin its Phase 3 Cornerstone trial by the end of 2026, with topline data expected in late 2028 and potential U.S. Food and Drug Administration (FDA) approval and commercial launch in 2030. Retail bulls eye $20. Retail sentiment surrounding XERS on Stocktwits flipped to 'bullish' from 'bearish' over the past 24 hours, amid a 100% jump in message volumes. One user expects EPS of $0.10 in the next quarter and the stock to climb to $20 by 2027. View this Stocktwits post The stock has gained about 55% so far in 2026. Also read: Oscar Health CEO Says Firm On Track For Strongest Financial Performance In History - OSCR Stock On Track To Hit Over 5 Year Highs For updates and corrections, email newsroom[at]stocktwits[dot]com.< Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business. 0 Comments / 0 New 1st ODI - NZ vs IND 2026 IND beat NZ by 5 wickets (D/L) method 2nd ODI - NZ vs IND 2026 Sat, 7 Nov, 2026 Match yet to begin. 5th T20 - NZ vs IND 2026 NZ beat IND by 7 wickets

Xeris Biopharma Holdings, Inc. reported third-quarter profit of $11.3 million on Thursday, or 6 cents per share. The Chicago-based company beat Wall Street expectations; three analysts surveyed by Zacks Investment Research had forecast earnings of 2 cents per share. Revenue for the period was $107.2 million, above the $101 million analysts expected. Xeris expects full-year revenue of $395 million to $405 million.